Corbus director granted RSUs and stock options

Corbus Pharmaceuticals director Brent Pfeiffenberger received new equity awards as part of his compensation.

Rhea-AI Filing Summary

Corbus Pharmaceuticals director Brent Pfeiffenberger received new equity awards as part of his compensation. On May 19, 2026, he was granted 7,500 restricted stock units that will settle in common shares and vest in three equal annual installments over three years, subject to continued service. He also received options on 24,700 shares of common stock at an exercise price of $9.15 per share, expiring on May 19, 2036, which will vest on the same three-year schedule under the company’s 2024 Equity Compensation Plan. Following these awards, his reported holdings include 7,500 shares of common stock and 24,700 stock options, all held directly.

Insider Trade Summary

Grant/Award: 32,200 shares

Grant/Award 2 txns

Insider Pfeiffenberger Brent

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	24,700	$0.00	$0.00
Grant/Award	Common Stock, par value $0.0001 per share	7,500	$0.00	$0.00

Holdings After Transaction: Stock options (right to buy) — 24,700 contracts (Direct); Common Stock, par value $0.0001 per share — 7,500 shares (Direct)

Footnotes (3)

1. F1. On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.
2. F2. This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.
3. F3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

Key Figures

RSU grant size: 7,500 units Option grant size: 24,700 options Option exercise price: $9.15/share +2 more

5 metrics

RSU grant size 7,500 units Restricted stock units granted May 19, 2026

Option grant size 24,700 options Stock options granted May 19, 2026

Option exercise price $9.15/share Exercise price for 24,700 stock options

Option expiration May 19, 2036 Expiration date of stock option grant

Shares held after grant 7,500 shares Total common stock holdings following RSU grant

Key Terms

restricted stock units ("RSUs"), vesting, stock options (right to buy), 2024 Equity Compensation Plan

4 terms

restricted stock units ("RSUs") financial

"On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"The RSUs will vest in three equal annual installments on each of the first three anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

stock options (right to buy) financial

"Stock options (right to buy)"

2024 Equity Compensation Plan financial

"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Brent Pfeiffenberger receive from Corbus Pharmaceuticals (CRBP)?

Brent Pfeiffenberger received 7,500 restricted stock units and stock options on 24,700 shares of Corbus Pharmaceuticals common stock. Both awards were granted on May 19, 2026 as part of his director compensation package, with future vesting conditions attached.

What are the vesting terms of Brent Pfeiffenberger’s new CRBP restricted stock units?

The 7,500 restricted stock units vest in three equal annual installments over three years. Each installment vests on the anniversary of the May 19, 2026 grant date, provided Pfeiffenberger continues to serve the company through each applicable vesting date.

What are the key terms of Brent Pfeiffenberger’s new CRBP stock options?

Pfeiffenberger received options on 24,700 CRBP shares with a $9.15 exercise price. These options vest in three equal annual installments over three years and expire on May 19, 2036, aligning with Corbus Pharmaceuticals’ 2024 Equity Compensation Plan.

How many Corbus Pharmaceuticals shares does Brent Pfeiffenberger hold after these awards?

After the May 19, 2026 awards, Pfeiffenberger is reported to hold 7,500 shares of Corbus Pharmaceuticals common stock directly. In addition, he holds options on 24,700 underlying common shares, subject to their vesting and future exercise.

Are Brent Pfeiffenberger’s CRBP equity awards open‑market transactions?

No, these are not open‑market trades. The Form 4 shows grant or award acquisitions of restricted stock units and stock options, issued at no cash cost to Pfeiffenberger as part of Corbus Pharmaceuticals’ equity compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	05/19/2026		A		7,500(1)	A	$0	7,500(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$9.15	05/19/2026		A		24,700		(3)	05/19/2036	Common Stock	24,700	$0	24,700	D

Explanation of Responses:

1. On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

2. This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

	/s/Meghan Houghton, Attorney-in-Fact for Brent Pfeiffenberger	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)